Pfizer (PFE), a pharmaceutical and biotechnology company, rose to great heights during the pandemic with its COVID-19 vaccine. However, it has spent the last few years attempting to reposition itself following the post-pandemic decline in COVID-related revenues. Many investors have written off the stock due to deteriorating sales of Comirnaty and Paxlovid, as well as concerns that its recovery strategies will fail to produce long-term growth. Pfizer stock has dipped 19.3% over the past 52 weeks and 9.7% ye ...